In rosiglitazone-treated obese patients with type 2 diabetes, improved insulin sensitivity and skeletal muscle oxidative enzyme activity is associated with an upregulation of PPARδ expression [35]. The gene discussed is INS; the disease is type 2 diabetes mellitus.